IRS2 Amplification

CI-VAR-00000238Explore in graph →CIViC 2598

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm1
IRS2 Amplification	Dual IGF-1R/InsR Inhibitor BMS-754807	Predictive	D	Supports Sensitivity Response	3	submitted	EID7075 Cell lines with IRS2 copy number gain had higher levels of ligand-stimulated activation of IGF-1R and AKT. IRS2 siRNA knockdown reduced IRS2 protein expression levels and decreased sensitivity to BMS-… (full text at CIViC) PMID 25527633 · Huang et al., 2015 · Open in CIViC	civic
Malignant Prostate Neoplasm1
IRS2 Amplification	Capivasertib	Predictive	C	Supports Resistance	2	submitted	EID10764 Phase 2 trial of capivasertib in solid cancer patients with AKT1/2/3 alterations. One patient with metastatic prostate cancer and in-frame AKT2 L78_Q79ins(HANTFVIRCL) that previously progressed on enz…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.